Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 2/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 3/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279651 | 0.80 | USP2 (0.43) | SMN1; SMN2USP2MMP13CDC7DBF4 | |
| SCHEMBL13006699 | 0.71 | USP2 (0.43) | USP2MLYCDMMP13CYP3A4LMNA | |
| SCHEMBL2629374 | 0.69 | NOS1 (0.40) | SMN1; SMN2CTSASMYD3 | |
| SCHEMBL13006688 | 0.69 | MMP13 (0.44) | USP2MMP13CYP3A4LMNAHDAC6 | |
| SCHEMBL12124452 | 0.67 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNA | |
| SCHEMBL27488152 | 0.66 | LTB4R2 (0.46) | SMN1; SMN2USP2LMNAHDAC3HDAC6 | |
| SCHEMBL8336083 | 0.66 | CYP17A1 (0.44) | SMN1; SMN2USP2MMP13LMNAHDAC3 | |
| SCHEMBL279790 | 0.65 | — | — | |
| SCHEMBL30600515 | 0.65 | KMT2A (0.48) | CYP3A4CYP2D6LMNAHDAC6 | |
| SCHEMBL27858608 | 0.64 | NOS1 (0.46) | SMN1; SMN2SMYD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | SMN1; SMN2 1437/4885USP2 3755/4885MLYCD 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.